TY - JOUR T1 - Altered Intercellular Communication and Extracellular Matrix Signaling as a Potential Disease Mechanism in Human Hypertrophic Cardiomyopathy JF - medRxiv DO - 10.1101/2021.12.18.21268004 SP - 2021.12.18.21268004 AU - Amy Larson AU - Christina J. Codden AU - Gordon S. Huggins AU - Hassan Rastegar AU - Frederick Y. Chen AU - Barry J. Maron AU - Ethan J. Rowin AU - Martin S. Maron AU - Michael T. Chin Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/23/2021.12.18.21268004.abstract N2 - Objectives To understand Hypertrophic Cardiomyopathy-associated alterations in gene expression and intercellular communication at the single cell level in left ventricular outflow tract lesions.Background Human hypertrophic cardiomyopathy (HCM) is considered a disorder of the sarcomere (i.e., cardiomyocytes) but the paradoxical association of nonmyocyte phenotypes such as fibrosis, mitral valve anomalies and microvascular occlusion is unexplained.Methods To understand the interplay between cardiomyocyte and nonmyocyte cell types in human HCM, single nuclei RNA-sequencing (snRNA-seq) was performed on myectomy specimens from HCM patients with left ventricular outflow tract obstruction and control samples from donor hearts free of cardiovascular disease.Results Clustering analysis identified a total of 34 distinct cell populations, which were classified into 10 different cell types based on marker gene expression. Differential gene expression analysis comparing HCM to Normal datasets revealed differences in sarcomere and extracellular matrix gene expression. Analysis of expressed ligand-receptor pairs across multiple cell types indicated profound disruption in HCM intercellular communication, particularly between cardiomyocytes and fibroblasts, fibroblasts and lymphocytes and involving integrin β1 and its multiple extracellular matrix (ECM) cognate ligands.Conclusions These findings provide evidence for intercellular interactions in HCM that link sarcomere dysfunction with altered cardiomyocyte secretion of ECM ligands, altered fibroblast ligand-receptor interactions with a variety of cell types and increased fibroblast to lymphocyte signaling, which can further alter the ECM composition, disrupt cellular function and promote nonmyocyte phenotypes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by American Heart Association Innovative Project Award 18IPA34170294 and by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number UL1TR002544 to M.T.C. A.L. was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number F32HL147492Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Tufts Medical Center gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the Gene Expression Omnibus database under accession numbers GSE161921 and GSE174691 https://www.ncbi.nlm.nih.gov/geo HCMHypertrophic CardiomyopathysnRNA-seqSingle nuclei RNA-sequencingECMExtracellular MatrixLVOTLeft Ventricular Outflow TractIVSInterventricular SeptumL-RLigand-ReceptorITGβ1Integrin-β1QCQuality ControlUMAPUniform Manifold Approximation and ProjectionGOGene OntologyTGF-βTransforming Growth Factor-β ER -